XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenues:        
Total revenues $ 236,178 $ 866,863 $ 1,830,639 $ 3,832,442
Operating expenses:        
Research and development 26,455,112 19,137,209 67,942,875 66,013,364
General and administrative 10,110,506 5,681,441 28,630,370 18,506,570
Total operating expenses 36,565,618 24,818,650 96,573,245 84,519,934
Loss from operations (36,329,440) (23,951,787) (94,742,606) (80,687,492)
Other income (expense):        
Interest income 896,710 637,438 2,380,678 2,018,302
Interest expense (1,984,046) (2,428,671) (7,634,442) (5,279,702)
Change in fair value of derivative liability 35,306,000 2,551,453 (75,670,977) 2,551,453
Gain (loss) on investment in affiliated entities 26,951,898 (485,841) 36,250,341 (1,409,156)
Net unrealized gain on available-for-sale equity securities 1,315,980 0 624,522 0
Other income (expense), net (136,644) 140,956 (714,246) 232,629
Gain on deconsolidation of Geneos 0 0 4,121,075 0
Net income (loss) before income tax benefit and share in net loss of Geneos 20,931,010 (23,536,452) (140,475,103) (82,573,966)
Income tax benefit 0 0 0 169,571
Share in net loss of Geneos (1,759,674) 0 (2,661,431) 0
Net income (loss) 19,171,336 (23,536,452) (143,136,534) (82,404,395)
Net loss attributable to non-controlling interest 0 445,759 1,063,757 707,214
Net income (loss) attributable to Inovio Pharmaceuticals, Inc. $ 19,171,336 $ (23,090,693) $ (142,072,777) $ (81,697,181)
Net income (loss) per share attributable to Inovio Pharmaceuticals, Inc. stockholders        
Basic (in dollars per share) $ 0.12 $ (0.23) $ (0.96) $ (0.83)
Diluted (in dollars per share) $ 0.11 $ (0.25) $ (0.96) $ (0.83)
Weighted average number of common shares outstanding        
Basic (in shares) 165,355,540 99,007,985 148,656,454 98,204,375
Diluted (in shares) 174,376,402 102,807,056 148,656,454 98,204,375
Convertible bonds        
Other income (expense):        
Gain (loss) on extinguishment of debt $ (8,177,043) $ 0 $ (8,177,043) $ 0
6.50% Convertible Senior Notes Due 2024        
Other income (expense):        
Gain (loss) on extinguishment of debt 3,087,595 0 3,087,595 0
Revenue under collaborative research and development arrangements        
Revenues:        
Total revenues 21,490 617,427 167,092 3,452,422
Revenue under collaborative research and development arrangements with affiliated entities        
Revenues:        
Total revenues 103,684 53,014 1,370,956 179,984
Miscellaneous revenue        
Revenues:        
Total revenues $ 111,004 $ 196,422 $ 292,591 $ 200,036